| Literature DB >> 32184422 |
Anna Maria Sulej-Suchomska1, Agnieszka Klupczynska2, Paweł Dereziński2, Jan Matysiak2, Piotr Przybyłowski3, Zenon J Kokot2.
Abstract
The use of illicit drugs causes unquestionable societal and economic damage. To implement actions aimed at combating drug abuse, it is necessary to assess illicit drug consumption patterns. The purpose of this paper was to develop, optimize, validate and apply a procedure for determining new psychoactive substances (NPSs) and classic drugs of abuse and their main metabolites in wastewater samples by using solid phase extraction (SPE) and high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). Moreover, detailed validation of the procedure was conducted. The developed SPE-HPLC-MS/MS procedure (within the sewage-based epidemiology strategy) allowed for the simultaneous, selective, very sensitive, accurate (recoveries ≥ 80.1%) and precise (CV ≤ 8.1%) determination of new and classic psychoactive substances in wastewater samples. This study is characterized by new scientific elements, especially in terms of the freeze-thaw and post-preparative stability of the selected psychoactive substances. This is the first time that NPSs (mephedrone and ketamine), the main metabolites of heroin (6-acetylmorphine, 6-AM) and marijuana (11-nor-9-carboxy-Δ9-tetrahydrocannabinol, THC-COOH) have been detected and monitored in Poland. This study is also the first to corroborate the data available from the EMCDDA and EUROPOL report and indicates that the retail market for cocaine is expanding in Eastern Europe.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32184422 PMCID: PMC7078280 DOI: 10.1038/s41598-020-61628-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic representation of the analytical procedure for the determination of illicit drugs in wastewater samples by using an SPE-HPLC-MS/MS-based system.
Retention times (t) and optimized MRM conditions used for HPLC-MS/MS analysis of psychoactive substances in wastewater samples.
| Compound | Abbreviation | tR (min) | Molecular mass (Da) | DP (V) | MRM1a (Quantifier) | CE 1 (V) | CXP 1 (V) | MRM2b (Qualifier) | CE 2 (V) | CXP 2 (V) | MRM ratioc (MRM1/MRM2) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6-acetylmorphine | 6-AM | 10.80 | 327.4 | 110 | 328.2 → 165.1 | 55 | 30 | 328.2 → 211.1 | 38 | 12 | 1.1 |
| 6-acetylmorphine -D3 | 6-AM-D3 | 10.80 | 330.4 | 71 | 331.2 → 211.2 | 37 | 40 | 331.2 → 271.2 | 37 | 45 | 3.1 |
| Amphetamine | AMPH | 9.10 | 135.2 | 30 | 136.1 → 91.1 | 26 | 16 | 136.1 → 119.1 | 9.0 | 11 | 3.9 |
| Amphetamine-D6 | AMPH-D6 | 8.85 | 141.2 | 51 | 142.1 → 93.1 | 23 | 16 | 142.1 → 125.1 | 14 | 12 | 1.5 |
| Benzoylecgonine | BEC | 11.50 | 289.3 | 75 | 290.1 → 168.1 | 29 | 16 | 290.1 → 105.1 | 45 | 19 | 2.3 |
| Benzoylecgonine-D3 | BEC-D3 | 11.50 | 292.3 | 81 | 293.1 → 171.1 | 30 | 16 | 293.1 → 105.1 | 53 | 10 | 8.3 |
| Ketamine | KET | 11.30 | 237.7 | 64 | 238.1 → 125.1 | 49 | 21 | 238.1 → 179.2 | 26 | 16 | 2.6 |
| Ketamine-D4 | KET-D4 | 11.30 | 241.7 | 61 | 242.1 → 211.2 | 24 | 11 | 242.1 → 224.1 | 25 | 21 | 1.0 |
| Mephedrone | MEPH | 11.00 | 177.2 | 61 | 178.2 → 145.1 | 30 | 25 | 178.2 → 144.1 | 39 | 23 | 2.0 |
| Mephedrone- D3 | MEPH-D3 | 11.00 | 180.2 | 61 | 181.2 → 148.2 | 30 | 25 | 181.2 → 163.2 | 20 | 16 | 1.9 |
| Methamphetamine | METH | 10.40 | 149.2 | 31 | 150.1 → 91.1 | 29 | 16 | 150.1 → 119.1 | 17 | 10 | 2.6 |
| Methamphetamine-D5 | METH-D5 | 10.40 | 154.2 | 50 | 155.1 → 121.1 | 16 | 16 | 155.1 → 92.1 | 28 | 12 | 1.0 |
| 3.4-methylenedioxyamphetamine | MDA | 10.50 | 179.2 | 28 | 180.2 → 105.1 | 32 | 18 | 180.2 → 135.1 | 27 | 12 | 1.7 |
| 3.4-methylenedioxyamphetamine-D5 | MDA-D5 | 10.50 | 184.3 | 51 | 185.2 → 168.1 | 17 | 16 | 185.2 → 110.1 | 33 | 10 | 4.2 |
| 3.4-methylenedioxy-methamphetamine | MDMA | 10.80 | 193.2 | 55 | 194.1 → 163.1 | 18 | 14 | 194.1 → 105.1 | 37 | 9.0 | 2.4 |
| 3.4-methylenedioxy-methamphetamine-D5 | MDMA-D5 | 10.80 | 198.2 | 70 | 199.1 → 165.1 | 19 | 14 | 199.1 → 107.1 | 34 | 8.0 | 3.1 |
| 3.4-methylenedioxy-ethylamphetamine | MDEA | 11.20 | 207.3 | 45 | 208.1 → 163.1 | 20 | 14 | 208.1 → 105.1 | 37 | 8.0 | 2.4 |
| 3.4-methylenedioxy-ethylamphetamine-D5 | MDEA-D5 | 11.20 | 212.2 | 52 | 213.1 → 163.1 | 20 | 8.0 | 213.1 → 105.1 | 37 | 9.0 | 2.8 |
| 11-nor-9-carboxy-Δ9-tetrahydrocannabinol | THC-COOH | 16.90 | 344.5 | −105 | 343.0 → 299.1 | −30 | −12 | 343.0 → 325.1 | −28 | −15 | 7.7 |
| 11-nor-9-carboxy-Δ9-tetrahydrocannabinol-D9 | THC-COOH- D9 | 16.90 | 353.5 | −117 | 352.0 → 308.1 | −30 | −12 | 352.0 → 334.2 | −30 | −17 | 2.0 |
aPrecursor ion → product ion I bprecursor ion → product ion II; DP: declustering potential; EP: entrance potential; CE: collision energy; CXP: collision cell exit potential; MRM: multiple reaction monitoring.
Performance data for the analysis of drugs of abuse (relative recovery in wastewater matrices, intra-day precision, and inter-day precision).
| Compounds | R2a | Linearity range | MDL | MQL | Recovery (n = 3) | Precision, CV(n = 3) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [ng/L] | Intra-day CV [%] | Inter-day CV | |||||||||||||||||||||||
| [%] | [%] | ||||||||||||||||||||||||
| Low | Medium | High | Low | Medium | High | Low | Medium | High | |||||||||||||||||
| D1b | D2c | D3d | D1 | D2 | D3 | D1 | D2 | D3 | D1 | D2 | D3 | D1 | D2 | D3 | D1 | D2 | D3 | ||||||||
| 6-AM | 0.9901 | 1.0–1000 | 0.5 | 1.0 | 88.5 | 80.4 | 80.1 | 98.6 | 97.5 | 100.8 | 99.6 | 101.3 | 96.6 | 4.6 | 4.1 | 5.9 | 7.2 | 4.3 | 2.3 | 2.8 | 4.6 | 4.6 | 4.3 | 2.3 | 5.3 |
| AMPH | 0.9954 | 5.0–1000 | 1.0 | 5.0 | 98.7 | 100.0 | 104.4 | 112.2 | 93.4 | 106.4 | 103.7 | 99.8 | 93.8 | 3.8 | 3.5 | 3.5 | 2.4 | 5.6 | 3.4 | 4.6 | 2.6 | 3.3 | 2.7 | 5.3 | 2.6 |
| BEC | 0.9935 | 1.0–1000 | 0.1 | 0.5 | 98.3 | 88.9 | 102.8 | 106.2 | 101.8 | 100.6 | 98.9 | 99.1 | 102.0 | 3.1 | 2.8 | 4.4 | 2.9 | 3.9 | 2.6 | 3.7 | 3.3 | 1.4 | 3.7 | 4.9 | 4.5 |
| KET | 0.987 | 1.0–1000 | 0.1 | 0.3 | 91.8 | 94.7 | 99.3 | 95.6 | 101.9 | 99.4 | 101.0 | 100.5 | 102.6 | 3.8 | 4.2 | 4.2 | 2.6 | 4.8 | 3.9 | 4.5 | 4.3 | 5.3 | 4.9 | 4.3 | 3.4 |
| MEPH | 0.9916 | 5.0–1000 | 0.1 | 0.3 | 111.6 | 97.3 | 88.1 | 108.8 | 106.1 | 96.2 | 100.3 | 97.5 | 99.6 | 5.9 | 5.2 | 3.5 | 8.0 | 4.7 | 5.0 | 7.4 | 2.3 | 5.8 | 2.7 | 3.5 | 4.2 |
| METH | 0.9954 | 1.0–1000 | 0.1 | 1.0 | 98.8 | 93.8 | 103.1 | 115.6 | 118.9 | 115.3 | 101.2 | 105.8 | 102.0 | 5.2 | 5.6 | 5.4 | 7.2 | 5.4 | 3.1 | 6.2 | 4.8 | 5.9 | 4.7 | 5.9 | 5.6 |
| MDA | 0.9939 | 5.0–1000 | 2.0 | 5.0 | 103.4 | 98.6 | 105.0 | 119.2 | 117.6 | 118.9 | 118.9 | 119.4 | 114.9 | 6.3 | 2.6 | 2.9 | 8.1 | 7.1 | 3.7 | 1.8 | 1.1 | 4.8 | 3.6 | 1.6 | 3.5 |
| MDMA | 0.9944 | 1.0–1000 | 0.1 | 0.3 | 100.5 | 98.3 | 104.4 | 103.6 | 88.2 | 110.6 | 101.6 | 117.5 | 108.8 | 2.4 | 3.6 | 3.6 | 0.9 | 1.5 | 4.8 | 2.1 | 3.3 | 6.4 | 4.5 | 5.5 | 7.4 |
| MDEA | 0.9944 | 1.0–1000 | 0.3 | 0.5 | 112.5 | 112.9 | 113.2 | 113.3 | 117.1 | 117.0 | 116.4 | 117.1 | 111.0 | 5.5 | 2.3 | 2.1 | 5.6 | 3.2 | 7.8 | 2.5 | 2.1 | 2.4 | 2.6 | 1.5 | 2.2 |
| THC-COOH | 0.988 | 5.0–1000 | 1.0 | 3.0 | 96.7 | 103.9 | 115.6 | 86.1 | 95.9 | 112.7 | 103.9 | 98.7 | 82.4 | 3.4 | 4.4 | 4.4 | 4.5 | 2.3 | 3.3 | 2.4 | 4.9 | 8.1 | 3.1 | 4.9 | 5.1 |
aR2Coefficient of determination, bD1-day 1, cD2-day 2, dD2-day 3.
Stability tests performed for the investigated drugs of abuse in wastewater samples.
| Compounds | Freeze-thaw stability | Short-term stability | Post-preparative stability | |||
|---|---|---|---|---|---|---|
| difference [%]a | SD [%] | difference [%] | SD [%] | difference [%] | SD [%] | |
| MDA | 0.9 | 0.3 | −0.3 | 2.4 | 2.2 | 2.2 |
| AMPH | 2.6 | 1.2 | −4.6 | 1.5 | 1.1 | 1.3 |
| MET | 3.8 | 1.1 | −6.0 | 1.5 | 2.2 | 2.5 |
| MDEA | 9.7 | 0.6 | 0.1 | 2.4 | 3.5 | 0.1 |
| MDMA | 8.0 | 2.0 | 4.3 | 0.7 | −0.5 | 0.5 |
| BEC | 2.8 | 0.8 | 0.2 | 0.1 | 2.2 | 1.6 |
| MEPH | 26.6 | 3.6 | 14.6 | 1.8 | −4.5 | 1.9 |
| KET | 18.9 | 2.1 | 11.9 | 1.1 | 1.6 | 0.8 |
| 6-AM | 6.8 | 3.2 | 1.8 | 4.9 | −5.0 | 0.7 |
| THC-COOH | 6.3 | 9.3 | 5.6 | 0.8 | −7.2 | 0.5 |
aDifference between the initial and final concentrations of target compounds.
Figure 2The concentrations of drugs of abuse in wastewater samples collected at a WWTP in Poznań (Poland) in autumn 2015.
Figure 3The concentrations of illicit drugs in wastewater samples collected at a WWTP in Poznań (Poland) in spring 2016.